Renaissance Capital logo

Lucid Diagnostics Priced, Nasdaq: LUCD

Makes diagnostic tests for esophageal precancer and cancer.

Industry: Health Care

Latest Trade: $9.60 +0.17 (+1.8%)

First Day Return: -16.0%

Return from IPO: -32.6%

Industry: Health Care

We are a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). We believe that our lead products, the EsoGuard® Esophageal DNA Test performed on samples collected with the EsoCheck® Esophageal Cell Collection Device, constitute the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent EAC deaths, through early detection of esophageal precancer in at-risk GERD patients. The technologies were highlighted in the NCI’s Annual Plan and Budget Proposal for FY2020 to Congress as one of the year’s significant advances in cancer prevention. We believe EsoGuard could have as great an impact in preventing EAC deaths as widespread Pap test screening has had in preventing cervical cancer deaths. We were formed in May 2018 as a subsidiary of our parent company, PAVmed Inc. (Nasdaq: PAVM), to license the technologies underlying EsoGuard and EsoCheck from Case Western Reserve University (CWRU).
more less
IPO News for Lucid Diagnostics
more
IPO Data
IPO File Date 09/22/2021
Offer Price $14.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/13/2021
Offer Price $14.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $70
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2018
Employees 4
Website www.luciddx.com